<div class="FTQUOTE"><begin quote><i>Originally posted by: <b>Printer</b></i>
Harriet:
I would refer you to an artical in the May 1997 issue of The New England Journal of Medicine. Titled HIGH-DOSE PANCREATIC-ENZYME SUPPLEMENT AND FIBROSING COLONOPATHY IN CHILDREN WITH CYSTIC FIBROSIS.
This article expressly excluded CREON from this problem. You will have to read the article not just the abstract.
Bill</end quote></div><br>I am looking into this a bit more. According to this article, the Creon exclusion was seen in a case study in the UK involving 14 patients. Given the cautions on the Creon site and prescribing info (will paste below), I don't think a case study that small rules it out.<br><br>Creon's website states this on the bottom of *every* page: <br><b>Important Safety Information</b><br>Fibrosing colonopathy, is associated with high-dose use of pancreatic enzyme replacement
in the treatment of cystic fibrosis patients. Exercise caution when doses of CREON
exceed 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase
units/kg of body weight per day).
<br><br>In the full prescribing info for Creon:<br><div class="FTQUOTE"><begin quote>5.1 Fibrosing Colonopathy<br>Fibrosing colonopathy has been reported following treatment with different pancreatic enzyme products. 5, 6 Fibrosing colonopathy is a rare, serious adverse reaction initially described in association with high-dose pancreatic enzyme use, usually over a prolonged period of time and most commonly reported in pediatric patients with cystic fibrosis. The underlying mechanism of fibrosing colonopathy remains unknown. Doses of pancreatic enzyme products exceeding 6,000 lipase units/kg of body weight per meal have been associated with colonic stricture in children less than 12 years of age.1 Patients with fibrosing colonopathy should be closely monitored because some patients may be at risk of progressing to stricture formation. It is uncertain whether regression of fibrosing colonopathy occurs.1 It is generally recommended, unless clinically indicated<br>that enzyme doses should be less than 2,500 lipase units/kg of body weight per meal (or less than 10,000 lipase units/kg of body weight per day) or less than 4,000 lipase units/g fat ingested per day [see Dosage and Administration (2.1)].<br>Doses greater than 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day) should be used with caution and only if they are documented to be effective by 3-day fecal fat measures that indicate a significantly improved coefficient of fat absorption. Patients receiving higher doses than 6,000 lipase units/kg of body weight per meal should be examined and the dosage either immediately decreased or titrated downward to a lower range.</end quote></div><br><br>When Creon gained it's FDA approval, a Q&A sheet released addressed the risk of this as well. <br>http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm149337.htm<br>